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Al~tract 
Objectives: To determine placental transfer of ketanserin and to assess the effect of serotonin-2 receptor blockade by ketanserin 
on serotonin- and phenykphrine-induced vasoconstriction. Study design: Five chronically instrumented pregnant ewes at 120 days 
gestation were injected with 20 mg ketanserin .v., and fetal and maternal rterial samples were obtained at predetermined intervals 
to assess placental transfer. Maternal and fetal responses of blood flows and pressures were determined after injection of serotonin 
(20 #g/kg) or phenylephrine (10 #g/kg) before and after ketanserin (0.75 mg/kg). Results: In the ewe, ketanserin s transferred across 
the placenta nd reaches measurable l vels in the fetal lamb. Ketanserin blocks the maternal and fetal serotonin-induced rise in 
arterial pressure, but not the serotonin-induced reduction in uterine blood flow. Conclusion: In the pregnant ewe,the serotonin- 
induced rise in maternal nd fetal blood pressure iseffectively antagonized by ketanserin, whereas the serotonin-induced r uction 
in uterine blood flow is not. 
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1. Introduction 
The circulation in untreated preeclamptic patients is 
characterized by an elevated blood pressure, reduced 
cardiac output, and an increased systemic vascular resis- 
tance with reduced perfusion of the placenta nd mater- 
nal organs including the kidney [1]. There is increasing 
evidence that preeclampsia s a trophoblast-dependent 
pathophysiological process that starts early in preg- 
nancy and is mediated by platelet activation, caused by 
damaged or dysfunctional endothelium leading to vaso- 
constriction [2,3]. 
Serotonin (5-hydroxytryptamine, 5-HT) is released 
following platelet aggregation and platelets are known 
to augment the effect of other vasoconstrictors through 
the release of serotonin [4]. Because platelet activation 
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and aggregation are associated with release of serotonin, 
this vasoactive substance and its receptors may be 
involved in the pathophysiology of preeclampsia [5,6]. 
The antihypertensive drug ketanserin (Ketensin ®) is a 
selective antagonist of serotonin receptors that belong to 
the 5-HT-2 category. Ketanserin lowers blood pressure 
through reduction of peripheral vascular resistance, 
while cardiac output remains virtually unaltered [7]. In 
addition to its antihypertensive effect, ketanserin also 
blocks the serotonin-induced aggregation of platelets 
[8]. From a theoretical point of view, these pharmaco- 
logic features make ketanserin an attractive choice for 
the antihypertensive treatment of patients with pre- 
eclampsia, and a number of small clinical studies have 
been published [9-13]. However, its potential use in 
pregnancy could be offset by unwanted side effects on 
the uteroplacental nd fetal circulations, the latter 
depending on placental transfer and fetal sensitivity to 
the drug. There are limited experimental data in preg- 
nant rats on the effects of ketanserin on maternal bemo- 
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dynamics and uteroplacental circulation [14], and no 
information on placental transfer is available. 
The present study was designed to determine in 
chronically instrumented pregnant ewes the placental 
transfer of ketanserin from the ewe to the fetal lamb, 
and to assess the effect of blockade of serotonin-2 recep- 
tors by ketanserin on serotonin- and phenylephrine- 
induced vasoconstriction. 
2. Materials and methods 
We studied five chronically instrumented pregnant 
Texel ewes with a median (range) weight of 62 (59-69) 
kg at 120 (115-135) days of gestation (term 145 days). 
Guidelines for the care and use of the animals, approved 
by the University Animal Experiments Committee, were 
followed. 
2.1. Surgical protocol 
The animals were acclimatized in the animal research 
facility for at least 3 days before operation. Twelve 
hours prior to surgery the animals were taken off food, 
but water remained freely available. After premedica- 
tion with ketamine (15 mg/kg bodyweight) and atropine 
(0.5 mg) i.m., anesthesia was induced with thiopen- 
taisodium (7-14 mg/kg) i.v. The ewe was intubated and 
ventilated, anesthesia was maintained with enflurane 2% 
in a 2:1 mixture of nitrous oxide and oxygen. Through 
a lower abdominal midline incision and a small incision 
in the uterus, the fetal hindlimbs were exteriorized. Poly- 
ethylene catheters were introduced in both fetal femoral 
arteries and in one femoral vein and threaded into the 
distal aorta and vena cava, respectively. Fetal weight 
was estimated by palpation and the uterine incision was 
closed. A precalibrated electromagnetic flow probe, 
(IS10-S-A-0, Skalar, Delft, The Netherlands) of appro- 
priate size (ID 2.5-4.5 mm) was placed around the main 
uterine artery on the side of the instrumented fetal amb, 
and a uterine vein was catheterized through a side- 
branch. All catheters were tunnelled, exteriorized 
through a flank incision and secured in a pouch attached 
to the flank. A catheter was placed in a maternal carotid 
artery and vein through an incision in the neck. All 
catheters were flushed daily with a saline solution con- 
taining amoxicillin (10 mg/ml), metronidazole (5 mg/ml) 
and heparin (100 U/ml). 
2.2. Experimental protocol 
Experiments were performed after at least 2 days of 
recovery with the ewes standing quietly in an individual 
cage with unlimited access to food and water. Maternal 
and fetal arterial pressures were measured using Gould 
Statham P 23 ID pressure transducers. Pressures and 
uterine artery blood flow signals were recorded on a 
Gould Brush 2800 recorder (Cleveland, USA), and 
stored on hard-disk with a sample frequency of 1 Hz. 
On the first experimental day we assessed placental 
transfer of ketanserin. After a 30-rain control period, a 
20-mg bolus of ketanserin was slowly injected into the 
maternal vein. Fetal and maternal arterial samples (1 
ml) were obtained at 5, 30, 60, 120, 180, and 240 min 
after injection. 
After immediate centrifugation, the plasma was 
stored at -20°C until assay. Ketanserin concentrations 
were determined fluorometrically after high-perform- 
ance liquid chromatography [15]. The minimum detec- 
table concentration was 2.0 ng/ml. 
In a second experiment, he efficacy of blockade of 
serotonin-2 receptors and of oL-l-adrenoreceptors by 
ketanserin was investigated. On consecutive days we 
measured responses after injection of serotonin (20 
~g/kg) or phenylephrine (10/zg/kg) into either a mater- 
nal or a fetal vein, both in the control state and 30 min 
after intravenous injection of a single dose of ketanserin 
(0.75 mg/kg of maternal or estimated fetal weight). 
Before, during and after experiments maternal and fetal 
arterial samples (1 ml) were drawn for immediate blood 
gas analysis (ABL 3, Radiometer, Copenhagen, Den- 
mark) and determination f hemoglobin concentrations 
(OSM2, Radiometer, Copenhagen, Denmark) to verify 
maternal and fetal health throughout the experiment. 
2.3. Data analysis 
Ketanserin concentrations are presented as median 
values (± ranges), all other variables as means 
( ± S.D.). We used Student's t-test for paired samples to 
assess differences between test periods. A P-value of 
< 0.05 was taken as the level of significance. 
3. Results 
All ewes and fetal lambs remained in good condition 
during the week after surgery and throughout the exper- 
iments. Before the administration of ketanserin to the 
ewe or the fetal amb median (range) values of maternal 
and fetal pH were 7.42 (7.40-7.43) and 7.35 (7.33-7.38), 
respectively; after ketanserin values were similar, 7.41 
(7.40-7.43) and 7.34 (7.30-7.35), respectively. Median 
(range) estimated fetal weight was 2500 (1500-3500) g, 
not different from the median (range) birthweight of 
2570 (1850-3850) g. 
3. I. Placental transfer of ketanserin 
Maternal and fetal arterial plasma concentrations 
following injection of 20 mg of ketanserin i to a mater- 
nal vein are presented in Fig. 1. The median half-life of 
ketanserin i  the arterial circulation of the ewe was 13 
min. Five minutes after injection of ketanserin the medi- 
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Fig. 1. Median concentrations of ketanserin ( g/ml) in maternal (@) 
and fetal (O) arterial plasma following intravenous administration f
20 mg ketanserin five pregnant ewes.The minimal detectable con- 
centration of ketanserin is indicated by the horizontal broken line. 
Numbers of samples with detectable vels between parentheses. 
an maternal arterial concentration reached a peak value 
of  153 ng/ral, with a wide range of  105-588 ng/ml. Low 
median concentrations of  6.1 ng/ml (range < 2.0-25.4 
ng/ml) were demonstrated in three of  five fetal lambs, 
whereas no ketanserin was detected in two fetuses. Thir- 
ty minutes after injection ketanserin was demonstrated 
in all five fetal lambs, with a median arterial concentra- 
tion of  18% (range 3-85%) of  that in the ewe. 
3.2. Blockade of serotonin-2 receptors by ketanserin 
3.2.1. Serotonin-2 blockade in the ewe 
Results are presented in Table 1A and Fig. 2. Intra- 
venous administration of ketanserin to the ewe in a dose 
of 0.75 mg/kg, was followed by a variable reduction in 
maternal arterial pressure by an average of  11% and an 
increase in uterine blood flow of  approximately 13% 
(P < 0.05); the effect on fetal arterial pressure was 
negligible. In the absence of  ketanserin, intravenous 
administration of  serotonin (20/~g/kg) to the ewe was 
associated with a monophasic pressor response and 
caused a maximum increase in mean maternal arterial 
pressure of  48%, a reduction in uterine blood flow of  
81%, and an increase in fetal arterial pressure of  32%; all 
changes were highly significant (P < 0.001). 
After intravenous administration of ketanserin, 
serotonin had hardly any effect on maternal arterial 
pressure, but uterine blood flow still fell by approx- 
imately 75% in all cases; the fall in uterine blood flow 
was similar to that observed after serotonin in the ab- 
sence of  ketanserin administration. Fetal arterial pres- 
sure showed a variable and non-significant increase of  
approximately 15%. 
3.2.2. Serotonin-2 blockade in the fetal lamb 
Results are summarized in Table 1 B. Intravenous in- 
Table 1 
Peak maternal nd fetal hcmodynamic responses to intravenous administration fscrotonin (20/~g/kg) tothe ewe (A) and to the fetal lamb (B), 
before and after ketanscrin (0.75 mg/kg) (n = 5) 
Before ketanserin After ketanserin 
Control values Changes after P-value 
serotonin 
Control values Changes after P-value 
scrotonin 
A 
Maternal arterial pressure 106 ± 13 +51 ± 23 <0.001 
(mmHg) 
Uterine blood flow 134 ± 37 -108 4- 29 <0.001 
(ml/min) 
Fetal arterial pressure 65 ± 7 +21 ± 7 <0.001 
(mmHg) 
B 
Maternal arterial pressure 99 ± 10 +8 -*- 9 
(mmHg) 
Uterine blood flow 166 ± 29 +8 ± 21 
(ml/min) 
Fetal arterial pressure 63 ± 10 +20 ± 8 
(mmHg) 
n.S .  
n .S .  
< 0.05 
94 ± 9 -7 ± 19 n.s. 
151 ± 43 - I I0 ± 44 <0.001 
59 ± 8 +9 ± 14 n.s. 
101 ± 9 +!6 ± 21 n.s. 
189 ± 16 -16 ± 19 n.s. 
62 ± I1 +7 ± 6 n.s. 
Values are means ± S.D.n.s., not significant (P > 0.05). 
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Fig. 2. Circulatory changes induced by i.v. injection of 20 tzg/kg 
serotonin into a single ewe before and after ketanserin blockade. 
Fig. 3. Circulatory changes induced by i.v. injection ot 10 #g/kg 
phenylephrine into a single ewe before and after ketanserin blockade. 
jection of serotonin (20/~g/kg) into the fetal lamb caused 
a significant rise in fetal arterial pressure of 32%. The 
small changes observed in maternal arterial pressure and 
in uterine blood flow were variable and not statistically 
significant. 
After administration of ketanserin, serotonin caused 
a small and non-significant increase in fetal arterial pres- 
sure (11%); maternal arterial pressure and uterine blood 
flow were not significantly affected. 
3.3. Blockade of et-l-adrenergic receptors by ketanserin 
3.3.1. Alpha-l-adrenergic blockade in the ewe 
Results are presented in Table 2A and Fig. 3. Intra- 
Table 2 
Peak maternal and fetal hemodynamic responses to intravenous administration of phenylephrine (10 #g/kg) to the ewe (A) and to the fetal lamb 
(B), before and after ketanserin (0.75 mg/kg) (n = 5) 
Before ketanserin After ketanserin 
Control values Changes after P-value 
phenylephrine 
Control values Changes after P-value 
phenylephrine 
A 
Maternal arterial pressure 108 ± 1 +38 ± 16 0,005 
(mmHg) 
Uterine blood flow 156 4- 13 -65 ± 53 0.01 
(ml/min) 
Fetal arterial pressure 67 4- 9 +5 4- 3 n.s. 
(mmHg) 
B 
Maternal  arterial pressure 104 ± 8 
(mmHg) 
Uterine blood flow 183 ± 40 
(ml/min) 
Fetal arterial pressure 67 ± 10 
(mmHg) 
+7 4- 10 n.s. 
-36 + 15 0.02 
+21 4- 10 0.001 
92 ± 17 +29 ± 8 0.001 
163 4- 13 -75 ± 25 0.002 
54 ± 12 +8 + 6 n.s. 
104 :~ 9 04-4  n.s. 
186 ± 20 -10 4- 19 n.s. 
67 ± 10 +7 4- 5 n.s. 
n,s., not significant (P > 0.05). 
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venous administration of phenylephrine significantly 
increased maternal arterial pressure by 35%, and 
reduced uterine blood flow by 41%; fetal arterial pres- 
sure showed a small and variable rise. Similar responses 
to phenylephrine were observed following ketanserin 
administration. 
3.3.2. AIpha-l-adrenergic blockade in the fetal lamb 
Results are presented in Table 2B. Phenylephrine in-
jection into the fetal amb induced a significant increase 
in fetal arterial pressure of approximately 31%. Mater- 
nal arterial blood pressure did not change significantly, 
but uterine blood flow showed a significant fall of 20%. 
After ketanserin injection into the fetal lamb, 
phenylephrine did not significantly affect fetal and ma- 
ternal arterial pressures or uterine blood flow. 
4. Discussion 
In our experiments in the pregnant ewe, ketanserin 
appeared to be transferred across the placenta. Fetal 
ketanserin levels were low, with marked variability, in- 
dicating limited transfer with a large inter-individual 
variation. The disappearance of ketanserin from mater- 
nal plasma in our sheep experiments, as judged from the 
median half-life of 13 min, was similar to that observed 
in non-pregnant humans [16]. Intravenous administra- 
tion of ketanserin a single dose of 0.75 mg/kg resulted 
in a small fall in maternal arterial pressure associated 
with a small increase in uterine arterial flow. Although 
these changes were statistically significant, they were 
variable and should be interpreted with care. We used 
normotensive ewes and maternal hemodynamic 
responses in conditions of hypertension could be dif- 
ferent. Maternal or fetal administration f ketanserin 
was not associated with changes in fetal hemodynamics. 
Maternal and fetal arterial blood gas samples howed 
normal values after ketanserin administration to the ewe 
or the fetus. These results indicate that ketanserin the 
single dose investigated has no deleterious effects on 
fetal condition. 
We found that serotonin i jection in the pregnant ewe 
was associated with a monophasic arterial pressor e- 
sponse, vasoconstriction f the uterine artery with a fall 
in uterine blood flow, and a rise in fetal arterial pressure. 
Our observations are in agreement with those by Lang 
et al. [17], also in pregnant sheep, but contrary to the 
findings of van Zwieten et al. [6], who observed a tri- 
phasic response to intravenous injection of serotonin in 
rats and other experimental nimals. After blockade of 
the 5-HT-2-receptors with ketanserin, the arterial 
pressor esponse to serotonin i  the ewe and in the fetal 
lamb was completely inhibited while uterine blood flow 
decreased as before. Previous studies howed that con- 
striction of the uterine vasculature induced by 2,5- 
dimethoxy-4-methylamphetamine (DOM), a highly 
selective 5-HT-2 agonist, can be completely inhibited by 
ketanserin [18,19]. The observation that in our experi- 
ments ketanserin did not modulate the uterine vascular 
response to serotonin suggests that in pregnancy, in 
addition to 5-HT-2 receptors, other receptors could be 
involved in the vasoconstrictor response of the ovine 
uterine artery to exogenous serotonin. 
Phenylephrine, a vasoconstrictor of sustained action 
mainly mediated by or-receptors, administered to the 
ewe increased maternal arterial pressure and reduced 
uterine blood flow. In our experiments ketanserin, in the 
relatively low dose of 0.75 mg/kg, did not inhibit the 
phenylephrine-induced pressor esponse in the ewe. In 
contrast, ketanserin a much higher dose of 10 mg/kg, 
as used by Nelson et al. [20], did show a significant ~,- 
blocking effect in sheep. In the fetal lamb, however, 
ketanserin clearly showed a-antagonist activity by 
blocking the rise in fetal arterial pressure induced by 
phenylephrine. 
Phenylephrine administered to the fetal amb not only 
caused arise in fetal arterial pressure, but also a variable 
but significant fall in uterine blood flow. This was an un- 
expected observation, for which we cannot present a 
logical explanation. The dose of 10/zg/kg of estimated 
fetal weight appears too low to cause an effective con- 
centration in the maternal circulation after placental 
transfer and, indeed, no changes in maternal blood 
pressure were apparent. 
In conclusion, our animal experiments have shown 
that ketanserin may prevent the serotonin-induced rise 
in maternal blood pressure, without an effect on a 
serotonin-induced r uction i  uterine blood flow. If we 
assume that serotonin contributes to the maternal 
vasoconstriction that is characteristic of hypertensive 
pregnancy [5], and if we extrapolate our findings in the 
pregnant ewe to the preeclamptic patient, our results 
suggest that ketanserin may reduce maternal hyperten- 
sion without an effect on uterine blood flow. 
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